Trials / Not Yet Recruiting
Not Yet RecruitingNCT05494723
Safety and Efficacy of YB-1113 in Treatment of POI
A Phase 1 Study of the Safety and Efficacy of YB-1113 in Treatment of Premature Ovarian Insufficiency (POI) Via Intravenous Infusion
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Bright Cell, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 39 Years
- Healthy volunteers
- Not accepted
Summary
This phase 1 study is to evaluate the safety and tolerability of YB-1113 administered via intravenous (IV) infusion in the treatment of premature ovarian insufficiency (POI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YB-1113 | Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC) |
Timeline
- Start date
- 2026-12-09
- Primary completion
- 2028-01-09
- Completion
- 2028-04-09
- First posted
- 2022-08-10
- Last updated
- 2025-12-23
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05494723. Inclusion in this directory is not an endorsement.